logo-loader

AEX Gold hails significant increase in exploration activity in first half

Last updated: 06:47 27 Aug 2020 EDT, First published: 03:05 27 Aug 2020 EDT

AEX Gold - AEX Gold hails significant increase in exploration activity in first half

AEX Gold Inc’s (LON:AEXG) (CVE:AEX) chief executive has hailed a “significant increase in activity” across its portfolio in the first half of its current year.

Eldur Olafsson added that following a C$72.7mln fundraise and AIM listing in July, the Greenland-focused gold group “is in a very strong position” and funded for planned work at its Nalunaq project, where it is currently performing exploration and pre-development work.

WATCH: AEX Gold on site in Greenland ahead of extensive exploration program

He added that the company is also undergoing additional exploration work across its wider portfolio in southern Greenland, where he believes there is “significant upside for investors in what is a materially undeveloped region”.

To accelerate exploration activities across the portfolio of gold assets in South Greenland, Olafsson also said that AEX is looking to secure additional non-equity funding in the form of a “modest working capital facility, vendor financing or similar”.

“Whilst we will look to execute on this facility as soon as possible, we are in a very strong position post-fundraise and will take time to ensure that any facility we enter into offers the best terms to our company and shareholders, and look forward to updating the market at the appropriate time,” the CEO said.

For the six months ended June 30, the company reported a net loss of C$3.4mln compared to a C$1.07mln loss in the prior year, which was attributed to the increased exploration and evaluation activities during the period.

Shares in AEX were 1.1% lower at 45.5p in late-morning deals on Thursday.

--Adds share price--

BenevolentAI advances novel ulcerative colitis treatment through Phase 1a trial

BenevolentAI (OTC:BAIVF) chief scientific officer Dr Anne Phelan joins Proactive's Stephen Gunnion with positive safety data from the Phase 1a, first-in-human, clinical study of BEN-8744 in healthy volunteers. Phelan explained that BEN-8744 is a potent, selective PD10 inhibitor, uniquely...

58 minutes ago